Related Experiment Video
Updated: Jun 1, 2026

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
Published on: October 4, 2021
Drug therapies for tardive dyskinesia: part 2
1University of Pittsburgh School of Medicine, Western Psychiatric Institute and Clinic, Pittsburgh, Pennsylvania 15213, USA. HowlandRH@upmc.edu
Abstract:
Tardive dyskinesia (TD) is a serious complication associated with the long-term use of dopamine receptor-blocking drugs. No drugs are approved by the U.S. Food and Drug Administration for treating TD. A number of drugs appear to have some benefit for its treatment, including branched-chain amino acids, piracetam (Nootropil(®), Nootrop(®), Nootropyl(®)), clonazepam (Klonopin(®)), levetiracetam (Keppra(®)), propranolol (Inderal(®)), and clonidine (Catapres(®)), and they would be clinically reasonable to try. Gabapentin (Neurontin(®) and others) has a good safety profile and would be appropriate to consider, although no controlled trials confirm its efficacy. The efficacy of ginkgo biloba should be balanced against its safety concerns. Essential fatty acids have not been shown to be effective. Antioxidant therapies, including vitamin E, melatonin, and vitamin B₆, could conceivably be used together with other drug therapies for the treatment of TD.
Related Concept Videos
Drug Therapy
Antianxiety Medications
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Antipsychotic Drugs: Therapeutic Uses and Side Effects
Despite these side effects, antipsychotics are used therapeutically for various purposes, including managing schizophrenia, preventing nausea and vomiting, curbing...
Antidepressant Drugs: MAOIs and Other Agents
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
Antipsychotic Drugs: Typical and Atypical Agents

